Key Drivers Behind AbbVie’s (ABBV) Performance
RS Investments, an investment management company, released its “RS Large Cap Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Abbvie Inc. (ABBV)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 2,623,100 | $549,591,912 | +36% | 0.1% | |
| 2. | 2,347,900 | $491,932,008 | +67% | 0.09% | |
| 3. | Citadel Investment Group Ken Griffin | 1,846,962 | $386,975,479 | +158% | 0.07% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,798,733 | $376,870,538 | +5% | 0.7% |
| 5. | Renaissance Technologies Jim Simons | 1,222,098 | $256,053,973 | +26% | 0.39% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | Officer | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | Officer | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | Officer | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | Officer | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | Officer | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $210.54 | 33,132 | 53,234 | 2025-03-31 | Filing | ||
| $209.49 | 25,700 | 86,366 | 2025-03-31 | Filing | ||
| $212.34 | 17,644 | 11,577 | 2025-03-14 | Filing | ||
| $210.53 | 6,168 | 388,929 | 2025-03-03 | Filing | ||
| $205.11 | 92,460 | 395,097 | 2025-02-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 173,917,865 | $36,439,271,075 | 0.66% | |
| 2. | 145,878,142 | $30,564,388,367 | 0.64% | |
| 3. | 79,962,967 | $16,753,840,846 | 0.69% | |
| 4. | 54,754,470 | $11,472,157,159 | 0.84% | |
| 5. | 41,149,734 | $8,621,693,054 | 0.62% |
News See All
AbbVie (ABBV) has a Stable and Highly Profitable Business Model
Renaissance Investment Management, an investment management company, released its Q1 2025 “Large Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here.
AbbVie (ABBV) Soared on Favorable Tailwinds
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Jim Cramer On AbbVie: Makes "Sense To Start a Position in the Stock"
“Or how about one of my absolute favorites right here too, AbbVie. Now here's a drug company with no patent cliff in sight whatsoever.
Jim Cramer Commented on 7 Hard-to-Own Safety Stocks
“When interest rates go up, even if they go up just a little, you can see lots of very good well-known stocks with juicy dividends just get pummeled.
20 Best Dividend Growth Stocks with High Yields
Dividend-paying stocks have been gaining popularity among investors due to their long-term advantages.
Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now
Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries.
10 Best Income Stocks to Invest in Now
Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive strategy.
AbbVie Inc. (ABBV): A Bull Case Theory
We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.
Billionaire Hedge Funds
